ImClone Investigational Site

Chicago, Illinois 60637

0 studies enrolling now · 14 studies all time

What they study most

Adenocarcinoma, Breast Cancer, Fallopian Tube Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Head and Neck Cancer, Hepatocellular Carcinoma, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer

Studies at this site

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer — Completed
Study of Ramucirumab in Ovarian Cancer — Completed
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma — Completed
Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients — Completed
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer — Completed
A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver — Completed
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before — Completed
Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck — Completed
A Study of Olaratumab in Soft Tissue Sarcoma — Completed
A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors — Stopped early
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer — Completed
Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy — Completed
A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma — Completed
Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer — Completed